Flucinar 0,025 % gel Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

flucinar 0,025 % gel

pharmaswiss ceska republika s.r.o. - Флуоцинолон ацетонид - 0,025 % gel

Flucinar N 0,25 mg/5 mg/g ointment Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

flucinar n 0,25 mg/5 mg/g ointment

pharmaswiss ceska republika s.r.o. - Флуоцинолон ацетонид и антибиотици - 0,25 mg/5 mg/g ointment

Flucinar 0,025 % ointment Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

flucinar 0,025 % ointment

pharmaswiss ceska republika s.r.o. - Флуоцинолон ацетонид - 0,025 % ointment

Abricort 0,25 mg/g ointment Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

abricort 0,25 mg/g ointment

Актавис ЕАД - Флуоцинолон ацетонид - 0,25 mg/g ointment

Abricort 0,25 mg/g cream Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

abricort 0,25 mg/g cream

Актавис ЕАД - Флуоцинолон ацетонид - 0,25 mg/g cream

Abricort N 0,25 mg/g + 5 mg/g cream  Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

abricort n 0,25 mg/g + 5 mg/g cream 

Актавис ЕАД - Флуоцинолон ацетонид и Неомицина - 0,25 mg/g + 5 mg/g cream 

Abricort N  0,25 mg/g + 5 mg/g ointment Bulgaristan - Bulgarca - Изпълнителна агенция по лекарствата

abricort n  0,25 mg/g + 5 mg/g ointment

Актавис ЕАД - Флуоцинолон ацетонид и Неомицина - 0,25 mg/g + 5 mg/g ointment

Delstrigo Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamivudine, tenofovir дизопроксил фумарат - ХИВ инфекции - Антивирусни средства за лечение на hiv инфекции, комбинации - delstrigo е показан за лечение на възрастни, заразени с ХИВ-1, Без да е минали или настоящи доказателства за резистентност към класа на ННИОТ, lamivudine или tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Pifeltro Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - ХИВ инфекции - Антивирусни средства за системно приложение - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

Comirnaty Avrupa Birliği - Bulgarca - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - Ваксини - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. Използването на тази ваксина трябва да бъде приложена в съответствие с официалните препоръки.